• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Former Medicines Patent Pool Head Greg Perry Joins Pharmaceutical Industry

15/12/2017 by Catherine Saez and William New, Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

A day after Greg Perry resigned as executive director of the Medicines Patent Pool, the pharmaceutical industry announced today that he will join the Geneva-based International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as an assistant director general.

The IFPMA press release says Perry will join in mid-February 2018 and “will have responsibility for IFPMA’s external outreach and stakeholder engagement in global health topics including innovation, access, and the international regulatory environment.”

The release says Perry will join “the re-vamped” IFPMA leadership team of Thomas Cueni, who became its director general in February 2017. Perry will work alongside Fumie Griego, who joined IFPMA from Merck and PhRMA in Washington, DC in May as assistant director general for strategic planning, policy and research.

The new team at IFPMA also includes James Pfitzer as director of the global ‘Access Accelerated – Moving NCD Care Forward’ initiative, who joined from the World Health Organization, and Helen Gallagher as director of Communications.

“I will be joining IFPMA at an exciting time – where the role … of the private sector as a major player in achieving universal healthcare is now regarded as essential. I have worked in a range of roles in the healthcare arena during the course of my career, but universal health care has been at the core of all of them. I very much look forward to joining the strengthened IFPMA leadership team and bringing solutions from another perspective,” Perry said in the release.

It is notable that IFPMA, traditionally a bastion of the innovative pharmaceutical industry, is expanding to include an expert with ties to the generics industry.

The release states: “Prior to his role as Executive Director of the Medicines Patent Pool, which he joined in 2013, Greg Perry was Director General of the European Generic Medicines Association (1999 -2013) in Brussels. Previously he worked as a partner in a UK public affairs company as a European Union policy advisor to corporate and non-governmental organisations, and before that as a Parliamentary Advisor to Members of the European Parliament.”

 

Image Credits: IFPMA

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Catherine Saez may be reached at csaez@ip-watch.ch.

William New may be reached at wnew@ip-watch.ch.

Creative Commons License"Former Medicines Patent Pool Head Greg Perry Joins Pharmaceutical Industry" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP Policies, Language, Themes, Venues, English, Finance, Health & IP, Health Policy Watch, Lobbying, Patents/Designs/Trade Secrets, WHO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Top Global Health stories

New WHO Director Tedros’s Opening Vision: People First

Enter The African Medicines Agency, Continent’s First Super-Regulator?

More health stories...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.